市场调查报告书
商品编码
1541335
2024-2032 年自然杀手细胞治疗市场报告(按治疗方法、应用、最终用户和地区)Natural Killer Cells Therapeutics Market Report by Therapeutics, Application, End User, and Region 2024-2032 |
IMARC Group年,全球自然杀手细胞治疗市场规模达28亿美元。罹患癌症的风险不断上升,加上老年人口不断增加,正在推动市场发展。
主要市场驱动因素:由于缺乏体力活动、不健康的饮食模式以及空气污染水平日益严重,患有癌症、传染病和肝臟疾病的人数不断增加,正在推动市场发展。
主要市场趋势:对临床研究的广泛投资,重点关注肿瘤靶向抗体策略,以尽量减少风险和毒性,这是推动市场发展的新兴趋势之一。
竞争格局:全球市场上一些知名的公司包括 Affimed GmbH、Bristol-Myers Squibb Company、Fate Therapeutics、Fortress Biotech Inc.、Glycostem Therapeutics、Innate Pharma SA、Kuur Therapeutics Inc. (Athenex Inc.)、Nkarta Inc.。武田製药股份有限公司及Ziopharm Oncology Inc. 等。
地理趋势:由于该地区政府机构为癌症患者制定了众多财务计划,北美在市场上表现出明显的主导地位。
挑战与机会:阻碍市场的挑战之一是製造流程的困难。这可以透过改进可扩展的生产方法来克服,以确保品质和功效。
联合疗法越来越受欢迎
将 NK 细胞疗法与其他治疗方式结合以增强治疗效果正在广泛关注。例如,Innate Pharma 的 Lumoxiti 是一种抗 CD22 免疫毒素,与 NK 细胞结合使用,可破坏和靶向毛细胞白血病中表达 CD22 的癌细胞。此外,这种方法利用了两种疗法的优势。除此之外,2024年5月,Coeptis Therapeutics Holdings, Inc.(一家为自体免疫、癌症和传染病开发创新细胞治疗平台的生物製药公司)推出了针对多种抗原的 SNAP-CAR NK 细胞。
监管机构的批准不断增加
政府机构日益关注提高 NK 细胞生产的可靠性和效率,这是一个重要的生长诱导因素。此外,他们鼓励将实验室研究转化为可行的临床疗法,这将在可预见的未来继续推动市场发展。例如,2024年4月,下一代NK细胞疗法的领先创新者Ingenium Therapeutics获得美国食品药物管理局(FDA)授予的治疗急性髓性白血病(AML)的孤儿药资格。
即时监控的需求不断增长
即时监测和资料分析广泛整合到 NK 细胞疗法开发中,正在提高治疗精度和患者治疗效果。此外,Bio-Techne 的 Ella 系统等平台可精确监测 NK 细胞扩增过程中细胞激素的产生,确保最佳的细胞功能。即时分析还允许研究人员动态调整培养条件,这有助于提高所产生的 NK 细胞的品质和有效性。这对市场产生正面影响。
The global natural killer cells therapeutics market size reached US$ 2.8 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 8.3 Billion by 2032, exhibiting a growth rate (CAGR) of 12.3% during 2024-2032. The rising risks of developing cancer, along with the expanding geriatric population, are propelling the market.
Major Market Drivers: The growing number of individuals with cancer, infectious diseases, and liver disorders, on account of the lack of physical activities, unhealthy dietary patterns, and the increasing air pollution levels, is catalyzing the market.
Key Market Trends: Extensive investments in clinical studies that focus on tumor-targeted antibody strategies to minimize risks and toxicities are among the emerging trends fueling the market.
Competitive Landscape: Some of the prominent companies in the global market include Affimed GmbH, Bristol-Myers Squibb Company, Fate Therapeutics, Fortress Biotech Inc., Glycostem Therapeutics, Innate Pharma S.A., Kuur Therapeutics Inc. (Athenex Inc.), Nkarta Inc., Takeda Pharmaceutical Company Limited, and Ziopharm Oncology Inc., among many others.
Geographical Trends: North America exhibits a clear dominance in the market, owing to numerous financial schemes by government agencies across the region for cancer patients.
Challenges and Opportunities: One of the challenges hindering the market is the difficulty in manufacturing processes. This can be overcome by improving scalable production methods to ensure quality and efficacy.
Increasing Popularity of Combination Therapies
Combining NK cell therapies with other treatment modalities to enhance therapeutic efficacy is gaining extensive traction. For example, Innate Pharma's Lumoxiti, an anti-CD22 immunotoxin, is adopted in conjunction with NK cells to destroy and target CD22-expressing cancer cells in hairy cell leukemia. Moreover, this approach leverages the strengths of both therapies. Besides this, in May 2024, Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
Growing Regulatory Approval
The rising focus among government agencies on enhancing the reliability and efficiency of NK cell production is acting as a significant growth-inducing factor. Furthermore, they are encouraging the translation of laboratory research into viable clinical therapies, which will continue to fuel the market over the foreseeable future. For example, in April 2024, Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
Rising Demand for Real-Time Monitoring
The widespread integration of real-time monitoring and data analytics into NK cell therapy development is enhancing treatment precision and patient outcomes. Moreover, platforms like Bio-Techne's Ella system enable precise monitoring of cytokine production during NK cell expansion, thereby ensuring optimal cell functionality. Real-time analytics also allow researchers to adjust culture conditions dynamically, which aids in improving the quality and effectiveness of the NK cells produced. This is positively influencing the market.
IMARC Group provides an analysis of the key trends in each segment of the market, along with the natural killer cells therapeutics market forecast at the global, regional, and country levels for 2024-2032. Our report has categorized the market based on therapeutics, application, and end user.
NK Cell Therapies
NK Cell Directed Antibodies
Currently, NK cell directed antibodies hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the therapeutics. This includes NK cell therapies and NK cell directed antibodies. According to the report, NK cell directed antibodies represented the largest market segmentation.
NK cell directed antibodies target natural killer cells to enhance their ability to recognize and destroy cancer cells. For example, Affimed's AFM13, a bispecific NK cell engager, targets CD30 on cancer cells and CD16A on NK cells.
Cancer
Gastrointestinal Diseases
Immunoproliferative Disorders
Others
Cancer currently exhibits a clear dominance in the market
The report has provided a detailed breakup and analysis of the market based on the application. This includes cancer, gastrointestinal diseases, immunoproliferative disorders, and others. According to the report, cancer represented the largest market segmentation.
The inflating need for effective cancer treatments drives the segment's growth. Recent product launches have underscored the potential of NK cell-based therapies in oncology. For instance, Fate Therapeutics' FT596 is an off-the-shelf, iPSC-derived NK cell therapy designed to target multiple cancer types, including B-cell malignancies.
Hospitals
Research Centers and Institutes
Others
Currently, research centers and institutes hold the majority of the total market share
The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, research centers and institutes, and others. According to the report, research centers and institutes represented the largest market segmentation.
Research centers and institutes offer high-quality reagents and technologies that streamline NK cell research, which is increasing the natural killer cells therapeutics market share. For example, Bio-Techne's Cloudz Human NK Cell Expansion Kit allows researchers to expand NK cells ex vivo efficiently.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
Advancements in biotechnology and a strong focus on innovative cancer treatments are primarily catalyzing the market in North America. According to the IMARC, the United States cancer immunotherapy market size is projected to exhibit a growth rate (CAGR) of 10.90% during 2024-2032. Besides this, collaborations between biotech firms are strengthening the regional market.
Affimed GmbH
Bristol-Myers Squibb Company
Fate Therapeutics
Fortress Biotech Inc.
Glycostem Therapeutics
Innate Pharma S.A.
Kuur Therapeutics Inc. (Athenex Inc.)
Nkarta Inc.
Takeda Pharmaceutical Company Limited
Ziopharm Oncology Inc.
(Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
May 2024: Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for autoimmune, cancer, and infectious diseases, introduced SNAP-CAR NK cells to target multiple antigens.
April 2024: Ingenium Therapeutics, a leading innovator in next-generation NK cell therapies, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of acute myeloid leukemia (AML).
January 2024: Indapta Therapeutics, Inc., a privately held biotechnology company developing IDP-023, a natural killer (NK) cell therapeutics for the treatment of cancer, announced the treatment of the first patients in its Phase 1 trial in multiple myeloma and non-Hodgkin's lymphoma.